Clinical Trials Browser

Non functioning pancreatic endocrine tumor × Clear all

NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03084770 2024-01-18

ASPEN

Gastrointestinal

Non functioning pancreatic endocrine tumor

NCT05907824 2023-09-13

Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm

Gastrointestinal

Non functioning pancreatic endocrine tumor

NCT03918759 2023-03-01

Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs

Gastrointestinal

Non functioning pancreatic endocrine tumor, Lymphatic Metastasis

NCT05566093 2022-10-04

EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors

Phase NA Unknown

Gastrointestinal

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell

NCT02420691 2020-10-30

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

Phase 2 Completed

21 enrolled 14 charts

Gastrointestinal

Non functioning pancreatic endocrine tumor, Thymus Neoplasms

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT02759718 2016-05-03

CgA

Phase 4 Unknown

Gastrointestinal

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell